The global pharma is expecting promising clinical trial results on up to 14 medicines as they take the decision to focus on developing a broader range of drugs, thus moving away from concentrating on those “blockbusters”.
The drugs in GSK’s pipeline are darapladib and MAGE-A3 – both of which have potentially high-reward but are also high-risk. GSK acquired full rights to the heart drug darapladib after acquiring Human Genome Sciences for $3 billion earlier this year. MAGE-A3 is a therapeutic vaccine which is currently being tested in lung cancer and melanoma.
Other drugs within GSK’s 2013/2014 pipeline include:
- Mepolizumab – used to treat severe asthma
- Drisapersen – used to treat Duchenne muscular dystrophy
- Migalastat – used to treat Fabry’s disease
Developing drugs to treat rare diseases is proving more and more popular with those pharmaceutical companies who want to spread their risk across both mass and niche therapeutic areas.
This is explained by Head of Drug Development at GSK, Patrick Vallance “Our strategy is to broaden the number of things coming through late-stage development by not focusing on the blockbuster model. Within this strategy, there will be things that turn out to be very big indeed. What the world has not been good at doing is spotting which ones they are early on.”
Are you looking for a position in the pharmaceutical industry?